ModernA's stock plummeted by 22% as pandemic hero faces survival struggles

Modernas stock (NASDAQ:MRNA) has taken another beating in the markets, with its price dropping nearly 21% today—a level not seen since April 2020. The biotech titantook a major blow to Wall Street after presenting a stark 2025 revenue forecast of $1.5 billion to $2.5 billion, which was well below the revised estimates of $2.92 billion from analysts.

The company has been struggling with declining sales since its RSV vaccine launch in late 2021, and now faces further headwinds from a shrinking Covid vaccine market, heightened competition, and falling vaccination rates globally. The recent drop in Modernas stock has raised concerns among investors about its ability to meet the high expectations set during the pandemic.

The company’s respiratory syncytial virus (RSV) shot has not lived up to its hype either, with negligible sales so far in 2024. Investors are now questioning whether Moderna can maintain the optimism that characterized its performance during the pandemic era. The warning signs detected by GuruFocus include factors like weak revenue growth and a fragile cash position.

Table of Contents

What’s Next for Moderna?

The company has announced significant cost-cutting measures to address its financial troubles. It plans to spend $1 billion in expenses this year (2025) and another $500 million in 2026, signaling a need to reduce operational costs while maintaining profitability. The aim is to become more profitable by diversifying its portfolio and expanding into new markets.

Moderna has ambitious expansion plans, with the goal of launching 10 new products by 2028. This includes cutting-edge vaccines for Covid-19 and the flu, as well as innovative treatments for other diseases in collaboration with partners like Merck (NYSE:MRK). The pipeline looks promising, but the company is facing a cash burn of over $3 billion in 2024, compared to its $18 billion peak during the pandemic.

The timing of these announcements could not be worse. Just before Moderna presents at the J.P. Morgan Healthcare Conference, which marks an important moment for the company to rally investor confidence, the stock has already fallen significantly. With cash reserves of over $9.5 billion, Moderna claims it has sufficient runway to transform itself into a new growth engine.

However, Wall Street remains skeptical. The stock’s decline over the past year has left it down more than 60%, and investors are waiting for clear evidence that Moderna can turn things around. The company will need to demonstrate not only continued progress in its pipeline but also a solid financial plan to show how it intends to recover.

Key Concerns for Investors

Revenue Growth: The weak performance of its RSV vaccine has dampened investor confidence, and the company’s revenue from these vaccines in 2024 was just $3 billion, down sharply from the $18 billion peak during the pandemic.
Diversification Efforts: While Moderna is investing heavily in new products, including combo vaccines for Covid-19 and flu, the pipeline has yet to deliver on its promises of breakthrough therapies for other diseases.
Cash Burn: The company’s cash burn rate remains a significant concern, with expenses exceeding revenues by nearly $2 billion in 2024.
Market Position: With Moderna operating in highly competitive markets—both in vaccines and medical treatments—the company faces intense pressure from established players like Pfizer (PFE) and Johnson & Johnson (JNJ).

The Road Ahead

The upcoming presentation at the J.P. Morgan Healthcare Conference could provide some clarity on Moderna’s strategy, but for now, investors are left wondering whether the company can sustain its performance in an environment marked by declining demand for its vaccines, rising competition, and falling vaccination rates.

While Moderna has ambitious plans to diversify into new markets and develop cutting-edge therapies, the cash burn rate remains a critical issue. Until the company can demonstrate that it can generate sufficient revenue to cover its expenses and build up a profit buffer, Wall Street will continue to question whether Moderna’s transformation plan will be successful.

In the short term, Moderna’s stock is likely to remain under pressure, unless the company can show that it has a solid strategy to turn things around. For now, investors are waiting for proof that Moderna can return to its former glory as a pandemic-era powerhouse.